S&P 500   3,375.76 (+0.07%)
DOW   27,945.28 (+0.17%)
QQQ   272.36 (-0.04%)
AAPL   458.84 (-0.26%)
MSFT   208.88 (+0.09%)
FB   261.01 (-0.11%)
GOOGL   1,511.25 (-0.36%)
AMZN   3,149.86 (-0.35%)
NVDA   460.35 (+0.57%)
CGC   17.24 (-0.46%)
BABA   252.38 (-0.53%)
TSLA   1,640.50 (+1.20%)
GE   6.65 (+0.76%)
MU   46.03 (-0.24%)
AMD   81.05 (-0.97%)
T   30.05 (+0.47%)
F   7.08 (+0.71%)
ACB   10.83 (+6.39%)
GILD   68.69 (+0.75%)
NFLX   482.15 (+0.17%)
DIS   130.37 (-0.45%)
BAC   26.56 (+0.80%)
BA   177.49 (+1.58%)
S&P 500   3,375.76 (+0.07%)
DOW   27,945.28 (+0.17%)
QQQ   272.36 (-0.04%)
AAPL   458.84 (-0.26%)
MSFT   208.88 (+0.09%)
FB   261.01 (-0.11%)
GOOGL   1,511.25 (-0.36%)
AMZN   3,149.86 (-0.35%)
NVDA   460.35 (+0.57%)
CGC   17.24 (-0.46%)
BABA   252.38 (-0.53%)
TSLA   1,640.50 (+1.20%)
GE   6.65 (+0.76%)
MU   46.03 (-0.24%)
AMD   81.05 (-0.97%)
T   30.05 (+0.47%)
F   7.08 (+0.71%)
ACB   10.83 (+6.39%)
GILD   68.69 (+0.75%)
NFLX   482.15 (+0.17%)
DIS   130.37 (-0.45%)
BAC   26.56 (+0.80%)
BA   177.49 (+1.58%)
S&P 500   3,375.76 (+0.07%)
DOW   27,945.28 (+0.17%)
QQQ   272.36 (-0.04%)
AAPL   458.84 (-0.26%)
MSFT   208.88 (+0.09%)
FB   261.01 (-0.11%)
GOOGL   1,511.25 (-0.36%)
AMZN   3,149.86 (-0.35%)
NVDA   460.35 (+0.57%)
CGC   17.24 (-0.46%)
BABA   252.38 (-0.53%)
TSLA   1,640.50 (+1.20%)
GE   6.65 (+0.76%)
MU   46.03 (-0.24%)
AMD   81.05 (-0.97%)
T   30.05 (+0.47%)
F   7.08 (+0.71%)
ACB   10.83 (+6.39%)
GILD   68.69 (+0.75%)
NFLX   482.15 (+0.17%)
DIS   130.37 (-0.45%)
BAC   26.56 (+0.80%)
BA   177.49 (+1.58%)
S&P 500   3,375.76 (+0.07%)
DOW   27,945.28 (+0.17%)
QQQ   272.36 (-0.04%)
AAPL   458.84 (-0.26%)
MSFT   208.88 (+0.09%)
FB   261.01 (-0.11%)
GOOGL   1,511.25 (-0.36%)
AMZN   3,149.86 (-0.35%)
NVDA   460.35 (+0.57%)
CGC   17.24 (-0.46%)
BABA   252.38 (-0.53%)
TSLA   1,640.50 (+1.20%)
GE   6.65 (+0.76%)
MU   46.03 (-0.24%)
AMD   81.05 (-0.97%)
T   30.05 (+0.47%)
F   7.08 (+0.71%)
ACB   10.83 (+6.39%)
GILD   68.69 (+0.75%)
NFLX   482.15 (+0.17%)
DIS   130.37 (-0.45%)
BAC   26.56 (+0.80%)
BA   177.49 (+1.58%)
Log in

OTCMKTS:ENDVEndonovo Therapeutics Stock Price, Forecast & News

$0.12
+0.02 (+16.08 %)
(As of 08/14/2020 01:22 PM ET)
Add
Compare
Today's Range
$0.10
Now: $0.12
$0.12
50-Day Range
$0.09
MA: $0.10
$0.13
52-Week Range
$0.01
Now: $0.12
$13.40
Volume9,640 shs
Average Volume142,311 shs
Market Capitalization$118.70 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
Endonovo Therapeutics, Inc. develops non-invasive electrocuetical devices for regenerative medicine. It is developing Electroceutical Therapy for the treatment of pain and post-surgical edema with a concentration on cosmetic surgeries, including breast augmentation, reduction and reconstruction surgery, rhinoplasty, and liposuction procedures. The company was incorporated in 2008 and is headquartered in Woodland Hills, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ENDV
CUSIPN/A
Phone800-489-4774

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$80,000.00
Book Value($0.03) per share

Profitability

Net Income$-6,440,000.00
Net Margins-5,033.33%

Miscellaneous

EmployeesN/A
Outstanding Shares1,002,549,000
Market Cap$118.70 million
Next Earnings DateN/A
OptionableNot Optionable
$0.12
+0.02 (+16.08 %)
(As of 08/14/2020 01:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ENDV News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Endonovo Therapeutics (OTCMKTS:ENDV) Frequently Asked Questions

How has Endonovo Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Endonovo Therapeutics' stock was trading at $0.3150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ENDV stock has decreased by 62.4% and is now trading at $0.1184.
View which stocks have been most impacted by COVID-19
.

Has Endonovo Therapeutics been receiving favorable news coverage?

Media headlines about ENDV stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Endonovo Therapeutics earned a daily sentiment score of -1.6 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
View the latest news about Endonovo Therapeutics
.

Are investors shorting Endonovo Therapeutics?

Endonovo Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 22,000 shares, an increase of 315.1% from the June 15th total of 5,300 shares. Based on an average daily volume of 251,800 shares, the short-interest ratio is currently 0.1 days.
View Endonovo Therapeutics' Short Interest
.

Who are some of Endonovo Therapeutics' key competitors?

What other stocks do shareholders of Endonovo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Energous (WATT), BIOLINERX LTD/S (BLRX), Ekso Bionics (EKSO), Marinus Pharmaceuticals (MRNS), Adamis Pharmaceuticals (ADMP), Advanced Micro Devices (AMD), Apache (APA) and Athersys (ATHX).

Who are Endonovo Therapeutics' key executives?

Endonovo Therapeutics' management team includes the following people:
  • Mr. Alan Brian Collier, Chairman, CEO, Interim CFO & Sec. (Age 53)
  • Mr. Michael Scott Mann, Pres (Age 62)
  • Mr. Donald Calabria, Chief Operating Officer
  • Mr. Steven Barnes, Sr. VP of Investor Relations
  • Bruce Garfield, Vice-Pres of Sales & Marketing

What is Endonovo Therapeutics' stock symbol?

Endonovo Therapeutics trades on the OTCMKTS under the ticker symbol "ENDV."

How do I buy shares of Endonovo Therapeutics?

Shares of ENDV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Endonovo Therapeutics' stock price today?

One share of ENDV stock can currently be purchased for approximately $0.12.

How big of a company is Endonovo Therapeutics?

Endonovo Therapeutics has a market capitalization of $118.70 million and generates $80,000.00 in revenue each year.

What is Endonovo Therapeutics' official website?

The official website for Endonovo Therapeutics is www.endonovo.com.

How can I contact Endonovo Therapeutics?

Endonovo Therapeutics' mailing address is 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367. The biotechnology company can be reached via phone at 800-489-4774 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.